The siderophore aerobactin is the dominant siderophore produced by hypervirulent Klebsiella pneumoniae (hvKP) and was previously shown to be a major virulence factor in systemic infection. However, strains of hvKP commonly produce the additional siderophores yersiniabactin, salmochelin, and enterobactin. The roles of these siderophores in hvKP infection have not been optimally defined. To that end, site-specific gene disruptions were created in hvKP1 (wild type), resulting in the generation of hvKP1⌬iucA (aerobactin deficient), hvKP1⌬iroB (salmochelin deficient), hvKP1⌬entB (enterobactin and salmochelin deficient), hvKP1⌬irp2 (yersiniabactin deficient), and hvKP1⌬entB⌬irp2 (enterobactin, salmochelin, and yersiniabactin deficient). The growth/survival of these constructs was compared to that of their wild-type parent hvKP1 ex vivo in human ascites fluid, human serum, and human urine and in vivo in mouse systemic infection and pulmonary challenge models. Interestingly, in contrast to aerobactin, the inability to produce enterobactin, salmochelin, or yersiniabactin individually or in combination did not decrease the ex vivo growth/survival in human ascites or serum or decrease virulence in the in vivo infection models. Surprisingly, none of the siderophores increased growth in human urine. In human ascites fluid supplemented with exogenous siderophores, siderophores increased the growth of hvKP1⌬iucA, with the relative activity being enterobactin > aerobactin > yersiniabactin > salmochelin, suggesting that the contribution of aerobactin to virulence is dependent on both innate biologic activity and quantity produced. Taken together, these data confirm and extend a role for aerobactin as a critical virulence factor for hvKP. Since it appears that aerobactin production is a defining trait of hvKP strains, this factor is a potential antivirulence target.
In the ongoing chess match between microbial pathogens and the human host, the pathogens as of late seem to be gaining the upper hand. Klebsiella pneumoniae is proving to be especially problematic and has evolved into two distinct epidemiologically and clinically defined pathotypes.The first and best-known pathotype, best termed "classical" K. pneumoniae (cKP), is presently responsible for the majority of K. pneumoniae infections in Western countries, which primarily occur in hospitals and long-term-care facilities (1). Importantly, cKP strains have received increased notoriety due to their propensity for acquiring antimicrobial resistance determinants, primarily carbapenemases, that make treatment challenging. The spread of New Delhi metallo--lactamase (NDM-1)-containing strains from India that are associated with medical tourism and, more recently, the extremely drug-resistant K. pneumoniae (XDR-KP) outbreak at the Clinical Center Hospital on the NIH campus have captured the attention of physicians, scientists, and the press (2, 3). XDR-KP is spreading globally and is primarily responsible for the increase in infections due to carbapenem-resistant bacteria in the U...